Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.

In patients harboring uncommon mutations, DCRs were 81.8, 88.9, and 57.1% in afatinib-, erlotinib-, and gefitinib-treated patients, although they did not reach statistical significance thresholds ( p = 0.182).

also in 111,027 other papers